Literature DB >> 2014152

High-frequency oscillatory ventilation versus intermittent mandatory ventilation: early hemodynamic effects in the premature baboon with hyaline membrane disease.

J P Kinsella1, D R Gerstmann, R H Clark, D M Null, W R Morrow, A F Taylor, R A deLemos.   

Abstract

We studied the hemodynamic consequences during the first 24 h of life in premature baboons (140 d) with hyaline membrane disease that were treated with high-frequency oscillatory ventilation (HFOV) or conventional intermittent mandatory ventilation (IMV). Cardiac output and organ blood flow were measured at three time-points using the radiolabeled microsphere technique. Seven of seven HFOV and six of eight IMV animals survived the 24-h period. By design, initial mean airway pressure (Paw) was higher in the HFOV group (p less than 0.01). HFOV Paw was progressively reduced during the study period because of improving oxygenation as measured by the arterial to alveolar oxygen ratio. In contrast, it was necessary to increase Paw in the IMV animals to maintain the arterial to alveolar oxygen ratio. By 23 h, the IMV group required higher Paw than the HFOV group (p less than 0.05) and had a lower arterial to alveolar oxygen ratio (p less than 0.05). We found no significant differences in left ventricular output, effective systemic flow, organ blood flow, or central venous pressure between the two groups at 3, 8, or 23 h. The HFOV strategy used in our study resulted in significant improvement in oxygenation during the initial 24 h of treatment without adverse effect on left ventricular output, cerebral blood flow, or central venous pressure. We conclude that when appropriate changes in Paw are made during HFOV in response to improvement in arterial oxygenation and changes in lung inflation as assessed by chest radiographs HFOV can be achieved without depressing cardiovascular dynamics more than during conventional therapy with IMV.

Entities:  

Mesh:

Year:  1991        PMID: 2014152     DOI: 10.1203/00006450-199102000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Meta-analysis of elective high frequency ventilation in preterm infants with respiratory distress syndrome.

Authors:  F Cools; M Offringa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

Review 2.  Chronic lung disease in the preterm infant. Lessons learned from animal models.

Authors:  Anne Hilgendorff; Irwin Reiss; Harald Ehrhardt; Oliver Eickelberg; Cristina M Alvira
Journal:  Am J Respir Cell Mol Biol       Date:  2014-02       Impact factor: 6.914

3.  Haemodynamic changes during high frequency oscillation for respiratory distress syndrome.

Authors:  B Laubscher; G van Melle; C L Fawer; N Sekarski; A Calame
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-05       Impact factor: 5.747

Review 4.  High frequency oscillation.

Authors:  A Greenough
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

5.  Hemodynamic effects of high-frequency oscillatory ventilation in severe pediatric respiratory failure.

Authors:  J A Gutiérrez; D L Levin; L O Toro-Figueroa
Journal:  Intensive Care Med       Date:  1995-06       Impact factor: 17.440

Review 6.  Bronchopulmonary dysplasia early changes leading to long-term consequences.

Authors:  Anne Hilgendorff; Michael A O'Reilly
Journal:  Front Med (Lausanne)       Date:  2015-02-12

7.  Hemodynamic effects of high frequency oscillatory ventilation with volume guarantee in a piglet model of respiratory distress syndrome.

Authors:  Jagmeet Bhogal; Anne Lee Solevåg; Megan O'Reilly; Tze-Fun Lee; Chloe Joynt; Lisa K Hornberger; Georg M Schmölzer; Po-Yin Cheung
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

Review 8.  Hemodynamic consequences of respiratory interventions in preterm infants.

Authors:  Arvind Sehgal; J Lauren Ruoss; Amy H Stanford; Satyan Lakshminrusimha; Patrick J McNamara
Journal:  J Perinatol       Date:  2022-06-11       Impact factor: 3.225

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.